Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13150731 | 0.85 | KCNA5 (0.33) | CHRNB4CHRNA3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL16316097 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL19286233 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL25159725 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL19286241 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL25159570 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL13421750 | 0.82 | HTR2A (0.32) | GAAL3MBTL1 | |
| SCHEMBL17470033 | 0.82 | HIF1A (0.37) | GAAL3MBTL1 | |
| SCHEMBL19286298 | 0.82 | HIF1A (0.37) | GAAL3MBTL1 | |
| SCHEMBL6264931 | 0.82 | GAA (0.31) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718823-B2 | 2, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2016-07-21 | — | — | US | disclosed |
| WO-2015027667-A1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 浙江医药股份有限公司新昌制药厂 (CN) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | NUDT1, PNP, SLC29A2 | CHRNB4 4754/4885CHRNA3 4756/4885CHRNB2 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.